We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Radius (RDUS) Announces Positive Data on Breast Cancer Drug
Read MoreHide Full Article
Radius Health, Inc. (RDUS - Free Report) announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant (RAD1901) in patients suffering from estrogen receptor positive (ER+) breast cancer. RAD1901, an oral selective estrogen receptor degrader (SERD), is being evaluated for potential use as an oral non-steroidal treatment for estrogen receptor positive breast cancer at high doses.
Radius Health’s share price shows that the company has outperformed the Zacks classified Medical Drugs industry year to date. The stock declined 7.7% compared with the industry’s gain of 5.7%.
As of the cut-off date of Apr 28, 2017, the fully enrolled study treated 40 patients at the 400 mg dose. The patients are all pretreated ER+, HER2-negative advanced breast cancer patients. The objective response rate (ORR) was 23% in heavily pre-treated patients with advanced ER+ breast cancer. In the 400 mg patient group with mature data, median PFS was 4.5 months and clinical benefit rate at 24 weeks was 42%. In fact, 38% of these patients previously received Faslodex, 40% received Ibrance (palbociclib) or another CDK inhibitor, 50% had an ESR1 mutation. It should be noted that 15 of the 40 patients remained on treatment as of the cut-off date.
Currently, Radius Health is evaluating RAD1901 in a phase I FES-PET study in patients with ER+, HER2-negative advanced breast cancerIn addition, the company entered a collaboration agreement with Novartis (NVS - Free Report) to explore RAD1901 in combination with Novartis’ LEE011 (Kisqali), a CDK 4/6 inhibitor, and BYL719 (alpelisib), an investigational phosphoinositide 3-kinase inhibitor.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Radius (RDUS) Announces Positive Data on Breast Cancer Drug
Radius Health, Inc. (RDUS - Free Report) announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant (RAD1901) in patients suffering from estrogen receptor positive (ER+) breast cancer.
RAD1901, an oral selective estrogen receptor degrader (SERD), is being evaluated for potential use as an oral non-steroidal treatment for estrogen receptor positive breast cancer at high doses.
Radius Health’s share price shows that the company has outperformed the Zacks classified Medical Drugs industry year to date. The stock declined 7.7% compared with the industry’s gain of 5.7%.
As of the cut-off date of Apr 28, 2017, the fully enrolled study treated 40 patients at the 400 mg dose. The patients are all pretreated ER+, HER2-negative advanced breast cancer patients. The objective response rate (ORR) was 23% in heavily pre-treated patients with advanced ER+ breast cancer. In the 400 mg patient group with mature data, median PFS was 4.5 months and clinical benefit rate at 24 weeks was 42%. In fact, 38% of these patients previously received Faslodex, 40% received Ibrance (palbociclib) or another CDK inhibitor, 50% had an ESR1 mutation. It should be noted that 15 of the 40 patients remained on treatment as of the cut-off date.
Currently, Radius Health is evaluating RAD1901 in a phase I FES-PET study in patients with ER+, HER2-negative advanced breast cancerIn addition, the company entered a collaboration agreement with Novartis (NVS - Free Report) to explore RAD1901 in combination with Novartis’ LEE011 (Kisqali), a CDK 4/6 inhibitor, and BYL719 (alpelisib), an investigational phosphoinositide 3-kinase inhibitor.
Radius Health, Inc. Price
Radius Health, Inc. Price | Radius Health, Inc. Quote
Zacks Rank and Stocks to Consider
Radius Health carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include VIVUS, Inc. and MEI Pharma, Inc. (MEIP - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>